Ibrutinib linked to invasive fungal infections - CLL Support

CLL Support

22,509 members38,657 posts

Ibrutinib linked to invasive fungal infections

lankisterguy profile image
lankisterguyVolunteer
2 Replies

In the past Idelalisib (Zydelig) was found to increase the risk of Pneumocystis in previously untreated patients. Now Ibrutinib has also been linked, fortunately prophylaxis is available and risks may be evaluated based on CD-4 T-cell levels. Talk to your CLL specialist to make certain this has been thoroughly considered for you specific case.

-

By Neil Osterweil Publish date: March 7, 2018

Vitals FROM BLOOD

mdedge.com/hematologynews/n...

The tyrosine kinase inhibitor ibrutinib (Imbruvica) may be associated with early-onset invasive fungal infections (IFI) in patients with hematologic malignancies, investigators caution.

-

French investigators identified 33 cases of invasive fungal infections occurring among patients who had been treated with ibrutinib as monotherapy or in combination with other agents. Of the 33 cases, 27 were invasive aspergillosis, and 40% of these were localized in the central nervous system. The findings were published in the journal Blood.

-

“IFI tend to occur within the first months of treatment and are infrequent thereafter. Whilst it seems difficult at this point to advocate for systematic antifungal prophylaxis in all patients, an increased awareness about the potential risk of IFI after initiating ibrutinib is warranted, especially when other predisposing factors are associated,” wrote David Ghez, MD, PhD, and colleagues at the Gustave Roussy Institute in Villejuif and other centers in France.

-

Although ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is generally considered to be less immunosuppressive than other therapies, it was associated with five cases of Pneumocystis jirovecii pneumonia in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib monotherapy in a 2016 report (Blood. 2016;128:1940-3). Of these five patients, four were treatment naive, suggesting that ibrutinib itself could increase risk for invasive opportunistic infections, Dr. Ghez and his colleagues noted.

-

If you are interested in reading more- see the box labeled "Related Posts" (top of right column on computer screens, way below on mobile devices).

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Cllcanada profile image
CllcanadaTop Poster CURE Hero

Aspergillosis may be an issue too, but can't use antifungal prophelactic like voriconazole with Imbruvica (ibrutinib), since they are highly interactive...

~chris

Beattiem-UK profile image
Beattiem-UK in reply to Cllcanada

Is there anything we can do ourselves to minimise the risks of getting aspergillosis?

You may also like...

Possible Risk of Fungal Infection with Ibrutinib

conclusion, this case demonstrates that the risk of fungal infection associated with ibrutinib is...

Cll/fungal infection of the lung

generated the second admission. Tests revealed a fungal infection in my lung so I was started on...

Infection, hospitalisation and future treatment with Ibrutinib or trial drug.

discus treatment for CLL and the consultant stated i am now eligble for Ibrutinib. I am also...

Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL

CD8+ T cells in 65 patients with CLL and 14 patients undergoing long-term ibrutinib therapy (median...

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)

64 patients in the ublituximab plus ibrutinib group and 40 (65%) of 62 patients in the ibrutinib...